MAPT and Alzheimer disease: Accordingly, the deletion of NLRP3, the master regulator of IL-1β, significantly improves cognitive impairment in AD mouse models, in addition to lowering Aβ-induced microglial activation in vitro, Aβ-deposition, or Tau pathology.